Takeda (France)

Recent papers from Takeda (France)

1. Vaccine Ligand Binding Assay DevelopmentBioanalysis · 2026
2. Mapping immune responses to TAK-003 dengue vaccine: immunogenicity across the clinical development programFrontiers in Immunology · 2026
3. Quantifying Transporter Activity: An Absolute Scaling Approach Using DigoxinMolecular Pharmaceutics · 2026
4. Vaccine Ligand Binding Assay Life Cycle Management, Assay Maintenance, Monitoring and TransferBioanalysis · 2026
5. Real-word evidence on healthcare resource use and associated costs in on-demand users of replacement therapies in von Willebrand disease in France: the FORvWARD study.2026
6. Abstract PS3-09-26: Real-world clinical characteristics, treatment patterns and outcomes among UK and French patients with early-stage, estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer treated with neoadjuvant chemotherapyClinical Cancer Research · 2026
7. Abstract PS3-09-05: Real-world clinical characteristics and treatment patterns among UK and French patients with a recent diagnosis (2020 onwards) of early-stage, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (ER+/HER2-eBC)Clinical Cancer Research · 2026
8. 2025 White Paper on Recent Issues in Bioanalysis: What is the Future of Bioanalytical LIMS? AI/ML Integration in Bioanalysis; Tear Sample Collection; Radiolabeled Mass Balance Studies; Chiral Assays; Bioanalysis of Antibody-Oligonucleotide & Bicycle Drug Conjugates ( PART 1A – Recommendations on Mass Spectrometry Assays, Chromatography, Sample Preparation and Regulated Bioanalysis Sampling, Validating, Analyzing & Reporting PART 1B – Regulatory Agencies’ Input on Regulated Bioanalysis/BMV)Bioanalysis · 2026
9. Pharmacokinetics, safety and tolerability, and efficacy of hyaluronidase-facilitated subcutaneous immunoglobulin 10% (HyQvia ® ) in Japanese patients with primary immunodeficiency diseasesSHILAP Revista de lepidopterología · 2026
10. 2025 White Paper on Recent Issues in Bioanalysis: Biomarkers Calibrators & Stability; Evaluation of NULISA; Neurofilament & Autoantibody Biomarker Assays; Removing IgM Interference; ELISpot & FluoroSpot Best Practices; Modular HD Cytometry; Single-cell Analysis Imaging Cytometry (PART 2A – Recommendations on Biomarkers Discovery, Development, Validation & Regulatory Approval, Ligand-Binding Assays (LBA) and Cell-Based Assays (CBA) PART 2B – Regulatory Agencies’ Input on Biomarkers, IVD/CDx and Biomarker Assay Validation (BAV))Bioanalysis · 2026
11. Confounding Effect of Hepatic Carboxylesterase 1 (CES1) Variability on Clopidogrel OxidationMolecular Pharmaceutics · 2025
12. Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygosity2025
13. Applying artificial intelligence to rare diseases: a literature review highlighting lessons from Fabry diseaseOrphanet Journal of Rare Diseases · 2025
14. TAK-003: development of a tetravalent dengue vaccineExpert Review of Vaccines · 2025
15. Pregnancy outcomes following unintentional exposure to TAK-003, a live-attenuated tetravalent dengue vaccineExpert Review of Vaccines · 2025
16. Three-year safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in Japan: Final analysis of an all-case postmarketing surveillance studyModern Rheumatology · 2025
17. Anti-arthritic effects of polyunsaturated fatty acid–rich supplementation combined with selective soluble epoxide hydrolase inhibitors in a collagen-induced arthritis mouse modelModern Rheumatology · 2025
18. PoD-BIN: A probability of decision Bayesian interval design for time-to-event dose-finding trials with multiple toxicity gradesThe Annals of Applied Statistics · 2025
19. Healthcare resource utilization and costs in immunodeficient patients receiving subcutaneous Ig: Real-world evidence from FrancePLoS ONE · 2025
20. Increasing incidence and prevalence of Hodgkin’s lymphoma in Finland: a population-based registry studyEuropean Journal of Public Health · 2025